market-trends is the sole category represented across all 1 tracked stories. Tri-Mast is most often covered alongside First Defense, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Tri-Mast
market-trends is the sole category represented across all 1 tracked stories. Tri-Mast is most often covered alongside First Defense, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. Their average consequence score of 5 runs below the beat's 5.9 for that window. We currently track 1 Healthcare story that mention Tri-Mast, all published on March 4, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Tri-Mast. Shared-story counts are live from our verified record — not editorial picks.
ImmuCell (NASDAQ: ICCC) has reported its unaudited 2025 financial results, highlighting a pivotal year of production expansion and backlog reduction for its bovine immunology products. The results were released alongside strategic updates from Pinetree Capital, a major institutional investor, signaling a period of maturing corporate governance.